CN1739539A - Use of puerarin in preparing medicine for treating myopia - Google Patents
Use of puerarin in preparing medicine for treating myopia Download PDFInfo
- Publication number
- CN1739539A CN1739539A CN 200510012806 CN200510012806A CN1739539A CN 1739539 A CN1739539 A CN 1739539A CN 200510012806 CN200510012806 CN 200510012806 CN 200510012806 A CN200510012806 A CN 200510012806A CN 1739539 A CN1739539 A CN 1739539A
- Authority
- CN
- China
- Prior art keywords
- puerarin
- group
- eye
- myopia
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the use of puerarin in preparing medicine for treating myopia, and belongs to the field of the medicinal application of puerarin. The medicine of puerarin for treating myopia has the advantages of high curative effect and less side effect.
Description
Technical field
The present invention relates to the purposes that a kind of puerarin is used to make treatment myopia medicine, it belongs to the application of puerarin pharmaceutical properties.
Background technology
Myopia is a medical conditions that extremely is difficult to treat, over nearly 20 years, various countries show keen interest to bathomorphic treatment, rely on high-tech development and going deep into to myopia etiology and animal experiment study, bathomorphic treatment has also entered a new stage, except that diversified operative therapy having occurred, myopia non-operative treatment spy is subjected to common concern.Think in the world that in recent years effectively Drug therapy only has the long-term eye dripping of atropine can prevent and treat or slow down the development of myopia, but, influenced popularization because of using atropine to have side effect such as mydriasis and adjusting paralysis.
Summary of the invention
Have the technological difficulties of side effect such as mydriasis and adjusting paralysis when the objective of the invention is to solve the use that has the medicine existence for the treatment of myopia now and provide the very little puerarin of a kind of side effect to be used to make the purposes of treatment myopia medicine.
The present invention solves the problems of the technologies described above the technical scheme that adopts to be: puerarin is used to make the purposes of treatment myopia medicine, and wherein: puerarin is as the application of preparation treatment myopia medicine.
Described medicine is an aqueous solution.
For showing the therapeutic effect of medicine of the present invention to myopia, the present invention has carried out zoopery.Laboratory animal is 44 of new healthy chicks of being born, male and female half and half, body weight 35-40g.Test drug is: 1,0.5% timoptol eye drops produced of pharmaceutical factory of Tianjin central authorities, 2, the 1% puerarin eye drop produced of Pinghu, Zhejiang pharmaceutical factory, 3, the 1% atropine eye water that provides of four-player people hospital preparation chamber, Xi'an.Experimental technique is: animal was divided into 4 groups (A, B, C, D groups) same day after birth at random, and 11 every group, wherein A is a model group, and B is the timolol group, and C is the puerarin group, and D is the atropine group, and a glance is handled, and other contrasts by eye.Modeling next day, B, C, D group are given and 0.5% timoptol eye drops, 1% puerarin eye drop and 1% atropine eye water spot right eye respectively, 1 time 2-3 drips,, January continuously, cut off the eyelid of fusion after January days for 2 times, by fixed optometrist with banded skiascope optometry, survey the eyes axiallength, after definite myopia forms, survey the eyes intraocular pressure.Extract eyeball afterwards, get 2 clavus balls (comprising the normal control group) for every group and fix, be equipped with in electron microscopic examination, all the other clavus balls are made light microscopy checking.Adopting SPSS statistics software to carry out statistical data handles.Experimental result is as follows:
1, puerarin is to the effect of chicken form deprivation myopia model
Organize average dioptric change in value puerarin and timolol are to the influence of chicken form deprivation myopia model as can be seen from each, and each group is average dioptric relatively to see Table 1.
Table 1 is respectively organized average dioptric comparison (X ± S)
| Group Group | Eye number n | Experimental eye Deprived eye (D) | Contrast eye Control eye (D) |
| A B C D | 10 9 9 10 | -9.05±1.14 -5.33±2.08 -3.37±1.09 -3.50±1.03 | 1.48±1.07 1.33±0.79 1.61±0.65 1.25±0.59 |
Statistical result shows: form deprivation eye and normal control eye relatively have utmost point significant difference (P＜0.01); Each medication group has been compared utmost point significant difference (P＜0.01) with model group; Timolol group and atropine group relatively have significant difference (P＜0.05); Puerarin group and atropine group be no significant difference (P＞0.05) relatively.
2, light microscopic is observed down
The chicken sclera is made up of the fibrous layer of shallow-layer and the cartilage layers of deep layer with human different, sees under the light microscopic that experimental eye contrasts an eye back utmost point portion sclerotic cartilage layer and thickens, the fibrous layer attenuation, and chondrocyte, dikaryocyte number increase, and density descends.Back utmost point portion sclerotic cartilage layer, fiber layer thickness relatively see Table 2 between each group.
The comparison of each group back utmost point portion fibrous sclera of table 2, cartilage layers thickness (X ± S)
| Group Group | Eye number n | Cartilage layers thickness Laginous sclera (μ m) | Fiber layer thickness Fibrous sclera (μ m) |
| A B C D E | 8 7 7 8 8 | 254.73±12.50 213.63±9.54 201.42±7.57 207.84±7.31 170.62±3.85 | 43.55±0.98 47.53±0.75 47.91±0.73 47.98±0.74 49.96±0.76 |
Statistical result shows: model group and matched group (E) relatively have utmost point significant difference (P＜0.01); Each medication group has been compared utmost point significant difference (P＜0.01) with model group; Timolol group and puerarin group and atropine group be no significant difference (P＞0.05) relatively.
From above-mentioned experimental result as can be known, Radix Puerariae have the effect that suppresses the chicken form-deprivation myopia preferably, its curative effect there was no significant difference of comparing with atropine, but the mydriasis of its no atropine waits side effect with the adjusting paralysis, therefore, compare with background technology, the present invention has the very little and eutherapeutic advantage of side effect, is the bathomorphic medicine of a kind of comparatively ideal treatment.
The specific embodiment
Method of the present invention is the application of puerarin as preparation treatment myopia medicine.Its medicine is the eye dropleting liquid solution that contains 1% puerarin.Its concrete using method is: the puerarin eye drop of employing 1% is used for the control of adolescent myopia oculopathy, local eye dripping, every day 2 times.
By myope's 120 examples of randomly drawing prescription on individual diagnosis, the age 9, between diopter-1.00D---6.00D, the men and women half and half to 13 years old, was divided into 3 groups at random by the consultation time sequencing, every group 40 example; Conventional examination of eyes is got rid of other ophthalmic before the treatment, and 1, vision adopts logarithmic visual acuity chart inspection and record.2, retinoscopy optometry behind the mydriasis.3, measure axiallength, intraocular pressure.First group is the blank group, refuses any treatment; The puerarin eye drop of second group of partial points 1%, every day 2 times; The two new bright eye water of the 3rd group of partial points, 1 treatment every day, 30 days is 1 course of treatment, has an eyesight test after the treatment, diopter, axiallength, intraocular pressure, March 1 time, tightly follows up a case by regular visits to 1 year.
Adopt the criterion of therapeutical effect (" preventing more bathomorphic views " " practical ophthalmology magazine " ' 1989-7 (3) ' 135 page) of formulation such as Xu Guang the: to promote the above person of 3 row be produce effects to the bore hole distant vision before all curees, Shi Zhihou executed and control; It is effective promoting 2-3 passerby; Promote 1 passerby or the nothing person of increasing for invalid; The above person of diopter minimizing-1.50D is a produce effects; Minimizing-1.00D is effective; Minimizing-0.50D or do not have increase and decrease for invalid.
Curative effect relatively after each organized medication
| Grouping | Produce effects | Effectively | Invalid | Total effective rate |
| Blank group experimental group matched group | 0 9 2 | 0 20 8 | 40 11 30 | 0 72.5％ 25％ |
Claims (2)
1, puerarin is used to make the purposes of treatment myopia medicine, it is characterized in that: puerarin is as the application of preparation treatment myopia medicine.
2, puerarin according to claim 1 is used to make the purposes of treatment myopia medicine, and it is characterized in that: described medicine is an aqueous solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510012806 CN1739539A (en) | 2005-09-09 | 2005-09-09 | Use of puerarin in preparing medicine for treating myopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510012806 CN1739539A (en) | 2005-09-09 | 2005-09-09 | Use of puerarin in preparing medicine for treating myopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1739539A true CN1739539A (en) | 2006-03-01 |
Family
ID=36092163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510012806 Pending CN1739539A (en) | 2005-09-09 | 2005-09-09 | Use of puerarin in preparing medicine for treating myopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1739539A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926788B (en) * | 2009-06-18 | 2012-12-19 | 刘力 | Cardiovascular/cerebral and ophthalmological medicines, and preparation and use thereof |
| CN104382997A (en) * | 2014-11-27 | 2015-03-04 | 罗英明 | Method for preparing puerarin eye drops |
| CN109044965A (en) * | 2018-10-17 | 2018-12-21 | 广州大光制药有限公司 | The medical composite for eye and medical usage of glycopyrronium bromide |
-
2005
- 2005-09-09 CN CN 200510012806 patent/CN1739539A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101926788B (en) * | 2009-06-18 | 2012-12-19 | 刘力 | Cardiovascular/cerebral and ophthalmological medicines, and preparation and use thereof |
| CN104382997A (en) * | 2014-11-27 | 2015-03-04 | 罗英明 | Method for preparing puerarin eye drops |
| CN109044965A (en) * | 2018-10-17 | 2018-12-21 | 广州大光制药有限公司 | The medical composite for eye and medical usage of glycopyrronium bromide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109803652A (en) | Ophthalmic pharmaceutical compositions and its associated uses | |
| US7915312B2 (en) | Physiological method of improving vision | |
| CN101219143B (en) | Use of anisodine in preparing medicament for treating amblyopia | |
| AU2024202353A1 (en) | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity | |
| CN1739539A (en) | Use of puerarin in preparing medicine for treating myopia | |
| CN108379558A (en) | Application of the interleukin 22 in the drug for preparing treatment persistent corneal epithelial defects | |
| CN112121104B (en) | Traditional Chinese medicine composition for relieving asthenopia and preventing and treating myopia | |
| CN104435541A (en) | Plaster for treating shortsightedness and preparation method thereof | |
| Davson | Vegetative Physiology and Biochemistry: The Eye | |
| Hardy et al. | Supporting patients undergoing cataract extraction surgery | |
| CN103860731A (en) | Pure traditional Chinese medicine preparation for treating eye disease | |
| Sun et al. | Effect of Recombinant Human Epidermal Growth Factor Associated with Conventional Drug Therapy on the Dry Eye Symptom Score in Patients with Dry Eyes after Cataract Surgery: A Systematic Review and Meta-Analysis | |
| Hamed et al. | Evaluation of Higher Order Aberrations after Cross-linking in patients with early Keratoconus | |
| Zhao et al. | Observation on the Curative Effect of Microsurgery in 154 Children with Strabismus and Analysis of Its Influencing Factors | |
| Schrader | Traditional cataract treatment and the healers perspective: Dialogue with western science and technology in Nigeria, West Africa | |
| HERSE | An ophthalmic survey of African patients presenting at rural eye clinics in South Africa | |
| Heidari et al. | Investigating the effect of Habolzahab (Iranian medicinal products based on Sabr, Hallila and rose flower) on the intraocular pressure of patients with open-angle glaucoma: A randomized, double-blind clinical trial | |
| RU2257900C1 (en) | Method for treating progressing myopia | |
| Nassar et al. | Effect of Patient Centered Care on Self-care practices and Satisfaction among Patients with Cataract Surgery | |
| Pattison | GDF-15 as a Biomarker for Glaucoma | |
| CN1086138C (en) | Chinese patent medicine for curing myopia | |
| CN116983339A (en) | External traditional Chinese medicine composition for preventing and treating teenager qi stagnation and blood stasis type myopia and application thereof | |
| CN115957216A (en) | Ophthalmic preparation, preparation method and application thereof | |
| CN116211984A (en) | A Chinese medicinal composition eye ointment for preventing and treating myopia of children and teenagers, and its preparation method | |
| ELiezer | Changes in Peripapillar Retinal Nerve Fiber Layer Analized by Td-Oct in Patients with Diabetic Retinopathy that Receive Panretinal Photocoagulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |